Abstract:Objective: Infantile hemangiomas frequently occur in the maxillofacial region as an extensive mass involving many vital structures. For this reason, many infants are found to have an unresectable hemangioma even at the initial diagnosis. In the present study simple transcatheter arterial sclerosing embolization (TASE) by using bleomycin-lipiodol and polyvinyl alcohol emulsion as embolization agents or the combination use of TASE with local injection of bleomycin-lipiodol has been employed with an attempt to improve the therapeutic results of these lesions. In this paper the clinical effectiveness and the technical safety of the two procedures for the huge maxillofacial hemangiomas in infants are presented and discussed. Methods: A total of fifty-seven infants with huge maxillofacial hemangiomas were enrolled in this study. Selective TASE followed by percutaneous injection sclerotherapy (IS) was adopted in 32 consecutive cases (study group). During TASE the feeding arteries of the lesion were embolized with pingyangmycin-lipiodol emulsion (PLE) and polyvinyl alcohol (PVA) particles in turn. Two weeks after TASE the residual hemangiomas were treated by percutaneous injection of pingyangmycin-lipiodol emulsion. Simple selective TASE was employed in another 25 cases (control group). The clinical data were analyzed and the results were compared between the two groups. Results: All the infants showed an excellent response to both TASE or TASE together with IS treatment. The size of hemangiomas body markedly decreased after the treatment. In 32 cases of the study group, a total of thirty-five times of TASE procedure were conducted with a mean of 1.1 times per case, while a total of 112 times of IS procedure were performed with a mean of 3.5 times per case. The curative rate was 78.1% (25/32), obvious effective rate was 21.9% (7/32) and ineffective rate was 0% in study group. The patients were followed up for a mean period of 13 months (6-16 months) and no recurrence was seen. A total of thirty-five times of simple TASE procedure were carried out in 25 cases of control group with a mean of 1.4 times per case. The curative rate and obvious effective rate were 76.0% (19/25) and 24.0% (6/25), respectively. The number of procedure times in study group was much smaller than that in control group, the difference between the two groups was statistically significant (P = 0.0205). No significant difference in therapeutic effectiveness existed between the two groups (P = 0.8495). No serious complications, such as pulmonary infarction or cerebral infarction, occurred in this series. Conclusion: As a mini-invasive, safe and effective technique, transcatheter arterial sclerosing embolization together with percutaneous injection sclerotherapy should be regarded as the treatment of first choice for huge maxillofacial hemangiomas in infants. This therapy carries fewer complications and leaves no ugly scar, and can also shorten the hospitalization days.

Transcatheter arterial sclerosing embolization with injection sclerotherapy for the treatment of huge and high-flow maxillofacial hemangiomas in infants

Injection of Triamcinolone Acetonide Acetate and Pingyangmycin for Infant Hemangioma at Privileged Sites

Interventional Embolization In Treatment Of Infantile Hepatic Hemangiomas

Intralesional Interstitial Injection of Bleomycin for Management of Extracranial Arteriovenous Malformations in Children

Successful treatment of steroid-resistant Kasabach-Merritt syndrome in infants with transcatheter arterial scleroembolization and vincristine

Transarterial arterial sclerosing embolization for the treatment of propranolol-resistant subglottic hemangioma: Feasibility and effificacy

Transarterial Embolization in Neonatal Kasabach–Merritt Syndrome

Pharmacological Therapies For Infantile Hemangiomas: A Clinical Study In 853 Consecutive Patients Using A Standard Treatment Algorithm

Pingyangmycin Sclerotherapy for Infantile Hemangiomas in Oral and Maxillofacial Regions: an Evaluation of 66 Consecutive Patients

Combination of Propranolol and Sclerotherapy for Treatment of Infantile Parotid Hemangiomas.

Intra-lesional Injection for the Treatment of Oral and Maxillofacial Lymphatic-Capillary Malformation in Infants and Children

Percutaneous Sclerotherapy of Arteriovenous Malformations of the Face Using Fibrin Glue Combined with OK-432 and Bleomycin after Embolisation.

Treatment of Early-stage Extracranial Arteriovenous Malformations with Intralesional Interstitial Bleomycin Injection: A Pilot Study.

Transcatheter arterial embolization for treatment of pulmonary sequestration in pediatric patients

Bleomycin A5 plus dexamethasone for control of growth in infantile parotid hemangiomas.

Injection of Diprospan with Methotrexate (MTX) in the Treatment of Infantile Hemangioma

Effects of Intervention Embolization Therapy and Intratumor Injection with Hardener on Head and Neck Gigantic Hemangioma

Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.

Percutaneous sclerotherapy of arteriovenous malformations of the maxillofacial soft tissues using fibrin glue combined with OK-432 and bleomycin following embolization in 13 consecutive patients

The changing face of complicated infantile hemangioma treatment

Sclerothrapy of giant lymphatic malformation in neonates